Peg-interferon

ApprovedSmall molecule

Peg-interferon is one of 137 small molecule programs targeting Alcoholic Fatty Liver Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

136

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alcoholic Fatty Liver DiseaseActive, not recruiting

Chronic HepatitisActive, not recruiting

MelanomaActive, not recruiting

Hepatitis CActive, not recruiting

Alcoholic Fatty Liver DiseaseApproved

Active, not recruiting

Chronic HepatitisPhase 1

Active, not recruiting

MelanomaPhase 1/Phase 2

Active, not recruiting

Hepatitis CPhase 2

Active, not recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Leukine

Sanofi

Phase 3

21 2

Tecentriq

Roche

Phase 3

11 3

Proleukin

IIovance Biotherapeutics, Inc.

Phase 3

27 4

Libtayo

Regeneron

Phase 3

6 5

Imjudo

AstraZeneca

Phase 3

2 6

Tuoyi

SSun Yat-sen University

Phase 3

4 7

Incomplete Freund's Adjuvant

EEastern Cooperative Oncology Group

Phase 3

20 8

Peg-interferon

Merck & Co.

Approved

1 9

Deltavit

HHyundai Pharmaceutical Co., LTD.

Epacadostat

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Post-ApprovalRecruiting

Alcoholic Fatty Liver Disease

NCT06368882

Clinical

Trials by Indication[1]

Chronic Hepatitis1 trial

Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)

Withdrawn· Merck & Co. logo

Merck & Co.·Phase 1·NCT01547312

Alcoholic Fatty Liver Disease1 trial

Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease（OCEAN PROJECT）

Recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 4·NCT06368882·1,500 enrolled

Melanoma1 trial

Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation

Completed·UUnknown Sponsor·Phase 1/2·NCT01959633·11 enrolled

Hepatitis C1 trial

Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients

Completed· Novartis logo

Novartis·Phase 2·NCT00759200·525 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Peg-interferon. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Peg-interferon compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Peg-interferon. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Merck & Co.

Peg-interferon

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Chronic Hepatitis1 trial

Alcoholic Fatty Liver Disease1 trial

Melanoma1 trial

Hepatitis C1 trial

References

Drug Info

Quick Facts

Related News